The authors reply

Crit Care Med. 2014 Dec;42(12):e798-9. doi: 10.1097/CCM.0000000000000681.

Authors

Steven M Opal¹, R Phillip Dellinger, Jean-Louis Vincent, Henry Masur, Derek C Angus

Affiliation

¹ Infectious Disease Division, The Alpert Medical School of Brown University, Providence, RI; Cooper Medical School of Rowan University, Camden, NJ; Department of Intensive Care, Erasme University Hospital, Brussels, Belgium; National Institutes of Health, Bethesda, MD; University of Pittsburgh School of Medicine, Pittsburgh, PA.

PMID: 25402303
DOI: 10.1097/CCM.0000000000000681

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Clinical Trials, Phase II as Topic / methods*
Clinical Trials, Phase III as Topic / methods*
Fibrinolytic Agents / therapeutic use*
Humans
Protein C / therapeutic use*
Sepsis / drug therapy*

Substances

Fibrinolytic Agents
Protein C